(Q43164242)

English

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program

scientific article published in March 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

0 references

1 reference

based on heuristic

inferred from title

Pellegrino Musto

1

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Adriano Venditti

9

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Alessandra Spagnoli

object named as

Alessandra Spagnoli

3

0 references

Valeria Santini

object named as

Valeria Santini

10

0 references

author name string

Luca Maurillo

2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Antonella Gozzini

4

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Flavia Rivellini

5

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Monia Lunghi

6

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Oreste Villani

7

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Maria Antonietta Aloe-Spiriti

8

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias

11

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

language of work or name

0 references

publication date

1 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

116

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

1485-1494

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

21 January 2018

Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

21 January 2018

Treatment options in myelodysplastic syndromes: a new frontier.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

21 January 2018

Myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide for the treatment of patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Consensus statement on iron overload in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Demethylating agents in myeloid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Azacitidine and the beginnings of therapeutic epigenetic modulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Current status of epigenetic treatment in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

A prognostic score for patients with lower risk myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

A limited number of 5-azacitidine cycles can be effective treatment in MDS.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot pharmacokinetic study of oral azacitidine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24894

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.24894

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43164242&oldid=1982730298"